The United Kingdom and the United States have reached a key bilateral deal that will keep zero levies on British medicine products going into the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase spending on drugs through the National Health Service (NHS). This pledge secures that tariffs on these crucial products will be held at nothing for a timeframe of 36 months.
This agreement comes after recent statements to significantly raise import taxes on branded drug imports, with figures mentioned reaching double the cost.
"This agreement with the Britain reinforces the worldwide climate for new treatments and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement declared.
Commercial Importance
Medicines constitute one of the the United Kingdom's largest exports to the US, which is by far the largest destination for leading UK drugmakers.
Export figures indicate that in the year prior to last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure made up 17.4% of all goods exports in that span.
"This guarantee secures employment, boosts funding and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official commented.
Key British Pledges
The agreement entails several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates exceeded twenty percent.
Broader Context
The deal takes place against a long-running tension between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were exacerbated by assertions that US customers were paying a premium for the same drugs than people in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
